This umbrella review assessed cancer risk with GLP-1 receptor agonists and tirzepatide across 38 meta-analyses from 2012 to 2026. Randomised and observational evidence were appraised separately for review quality, overlap and certainty. In 48 placebo-controlled trials with 94 245 participants, thyroid cancer showed no significant association (OR 1·37, 95% CI 0·82-2·31). Pancreatic, colorectal and breast cancer were also not significant, and overall cancer showed no increase (OR 1·05, 0·98-1·13). Observational syntheses suggested lower hepatocellular carcinoma risk (HR 0·60, 0·41-0·88), but four reviews overlapped heavily. No outcome reached high certainty, and median trial follow-up of about 70 weeks cannot address long-latency cancers.
Why it is interesting: Cancer safety evidence for increasingly used GLP-1 drugs rests on trials with a median follow-up of about 70 weeks. Reviews disagreed on thyroid and colorectal cancer mainly through comparators, pooling methods and handling of zero-event trials.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.